“Lest we forget you - methylene blue …”

• Verfasst von: Schirmer, Rolf Heiner [VerfasserIn]
• Verfasst von: Adler, Heike [VerfasserIn]
• Verfasst von: Pickhardt, Marcus [VerfasserIn]
• Verfasst von: Mandelkow, Eckhard [VerfasserIn]
• Titel: “Lest we forget you - methylene blue …”
• Verf.angabe: R. Heiner Schirmer, Heike Adler, Marcus Pickhardt, Eckhard Mandelkow
• E-Jahr: 2011
• Jahr: 12 February 2011
• Umfang: 10 S.
• Fussnoten: Gesehen am 11.10.2022
• Titel Quelle: Enthalten in: Neurobiology of aging
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1980
• Jahr Quelle: 2011
• Band/Heft Quelle: 32(2011), 12, Seite 2325.e7-2325.e16
• ISSN Quelle: 1558-1497
• DOI: doi:10.1016/j.neurobiolaging.2010.12.012
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Alzheimer's disease
• Sach-SW: History
• Sach-SW: malaria therapy
• Sach-SW: Medical application
• Sach-SW: Methylene blue
• Sach-SW: prodrug of azure B
• Sach-SW: tau aggregation inhibitor
• K10plus-PPN: 1818584085

Abstract

Methylene blue (MB), the first synthetic drug, has a 120-year-long history of diverse applications, both in medical treatments and as a staining reagent. In recent years there was a surge of interest in MB as an antimalarial agent and as a potential treatment of neurodegenerative disorders such as Alzheimer's disease (AD), possibly through its inhibition of the aggregation of tau protein. Here we review the history and medical applications of MB, with emphasis on recent developments.